Interleukin-2 (IL-2) has been identified more than 30 years ago and primarily been described as a factor acting on conventional T cells to promote their activation and proliferation.
1 Due to its T-cell activating and expanding properties, IL-2 has been introduced early into the immunotherapy of cancer patients, either as a single agent or in combination with other cytokines or chemotherapy.
1 However, over the last several years it has become clear that IL-2 not only has beneficial properties, but also can expand regulatory T (T reg ) cells.
1
T reg cells are involved in self-tolerance, immune homeostasis, prevention of autoimmunity and suppression of immunity to pathogens. 2 The forkhead transcription factor FOXP3 is essential for T reg -cell development and function, as mutations in FOXP3 cause autoimmunity in mice and the IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked) syndrome in humans.
2
In tumor-bearing individuals, T reg cells are increased in numbers both in the local tumor microenvironment and in the peripheral blood, and can contribute to the overall immunosuppression.
3 In several human tumors, T reg cells even have prognostic significance and their abundance can be correlated with the stage of disease.
3 Depletion of T reg cells has been suggested as a therapeutic option, with early clinical trials using an IL-2 immunotoxin showing promising results.
3
One important and yet unresolved aspect in tumor immunology is how and where T reg cells in tumor patients develop. Peripheral induction is one possibility, whereby tumor antigen-specific T cells might be converted into FOXP3-expressing T reg cells with suppressive functions within the tumor microenvironment. An alternative scenario would be the accumulation of T reg cells generated in the thymus, which would be attracted to the tumor site by specific factors such as chemokines.
Several studies have assessed the abundance and function of human T reg cells after IL-2 administration, and the overall consensus was that IL-2 augments their frequency. [4] [5] [6] Possible explanations for such an increase were peripheral expansion of T reg cells but also altered migratory activity.
7 However, none of these studies assessed how IL-2 influenced the thymic output of T reg cells and whether this would interfere with efficient antitumor immune responses.
In a recent study, 8 we investigated how IL-2 treatment influences T reg -cell numbers and function in colorectal cancer patients undergoing a combined immunochemotherapy. We observed increased levels of T reg cells, as determined by a combined staining for CD4, FOXP3 and CD25 in the peripheral blood of these patients at the start of therapy, confirming previously published observations.
3 These cells expressed typical T reg -cell markers including CTLA-4 and GITR and had normal immunosuppressive functions. Next, we assessed the influence of IL-2 on the number of total T reg cells after completion of therapy, finding an expansion of the pool of T reg cells in IL-2 treated patients. This is in line with previously published studies, which also reported elevated numbers of T reg cells after treatment with IL-2. [4] [5] [6] Similar to conventional T cells, T reg cells can be distinguished into memory and naïve subsets, according to the surface expression of CD45RA. Valmori et al. were the first to report that a subset of naïve T reg cells exists that is anergic following stimulation in the absence of IL-2, exerts ex vivo cell-cell contact-mediated suppressor functions yet proliferates in response to stimulation with autologous antigen-presenting cells.
9 These observations indicate that a high proportion of these cells have self-reactive T-cell receptors and hence that they are derived from the thymic T reg -cell compartment. 9 The relationship between memory and naïve T reg cells was further delineated in humans using genomic and functional approaches by Miyara et al. who clearly established that naïve T reg cells are an important subpopulation of human FOXP3 + T reg cells.
10
Using a similar gating strategy, which included the assessment of CCR7 expression to distinguish between central-and effector-memory T reg cells, we could detect
Augmented numbers of regulatory t cells contribute to the overall immunosuppression in tumor patients. Interleukin-2 has been widely used in the clinics in anticancer therapy, yet evidence has accumulated that the major drawback, limiting clinical efficacy, is the expansion of regulatory t cells, which aggravates immunosuppression. treatment results in an expansion of naïve T reg cells in all immunological cell compartments. This was mainly due to an increased thymic output, as assessed by analyzing TRECs in the sorted naïve T reg cells from these animals.
Taken together, our data supports an overall increase in T reg cells in tumor patients with an expansion of newly generated naïve T reg cells post IL-2 therapy as a major mechanism of the T reg -cell expansion in IL-2 treated tumor patients (Fig. 1) . This finding has implications for the future direction on how to target T reg cells in tumor patients. Depletion of T reg cells, e.g., by the administration of T reg -cell targeting antibodies or immunotoxins, will only result in a short-term depletion of peripheral T reg cells. Long-term reduction of T reg cells will warrant therapeutic strategies reducing the thymic output of T reg cells, thus properly circumventing their immunosuppressive functions in tumor patients.
an increase in naïve T reg cells before the initiation of immunotherapy. This increase in naïve T reg cells was even more pronounced after IL-2 administration and assessment of their suppressive function showed immunosuppressive activity comparable to that of memory T reg cells. One approach to determine the vicinity of T cells to the thymus is to determine the number of T-cell receptor excision circles (TRECs). Assessing TRECs in sorted naïve T reg cells from healthy donors and patients, before and after therapy, indicated that naïve T reg cells are enriched in thymus-derived T reg cells even before therapy, but particularly after the administration of IL-2, suggesting that IL-2 primarily acts on the thymus to produce additional T reg cells that join those already present in the tumor microenvironment and the peripheral blood of these patients.
To substantiate this observation, we administered IL-2 in a murine model system and could show that the IL-2 Figure 1 . Interleukin 2 administration results in a preferential expansion of regulatory t (t reg ) cells. Administration of interleukin-2 to tumor patients only results in a weak activation and expansion of potentially tumor-counteracting effector t cells, while memory t reg cells in the periphery as well as the naïve thymic t reg -cell pool are consistently expanded.
